Protagonist Therapeutics Inc (PTGX)
41.04
-1.63
(-3.82%)
USD |
NASDAQ |
Nov 14, 16:00
41.04
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Free Cash Flow: 229.23M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | 229.23M |
| June 30, 2024 | 230.85M |
| March 31, 2024 | -64.16M |
| December 31, 2023 | -70.84M |
| September 30, 2023 | -119.49M |
| June 30, 2023 | -117.84M |
| March 31, 2023 | -105.35M |
| December 31, 2022 | -108.93M |
| September 30, 2022 | -104.36M |
| June 30, 2022 | -107.73M |
| March 31, 2022 | -118.01M |
| December 31, 2021 | -108.97M |
| September 30, 2021 | -100.82M |
| June 30, 2021 | -88.45M |
| March 31, 2021 | -85.86M |
| December 31, 2020 | -72.96M |
| September 30, 2020 | -68.47M |
| June 30, 2020 | -66.04M |
| Date | Value |
|---|---|
| March 31, 2020 | -41.65M |
| December 31, 2019 | -42.49M |
| September 30, 2019 | -38.18M |
| June 30, 2019 | -33.67M |
| March 31, 2019 | -51.92M |
| December 31, 2018 | -50.43M |
| September 30, 2018 | -54.44M |
| June 30, 2018 | -4.503M |
| March 31, 2018 | -1.736M |
| December 31, 2017 | 3.206M |
| September 30, 2017 | 7.679M |
| June 30, 2017 | -39.83M |
| March 31, 2017 | -35.23M |
| December 31, 2016 | -30.32M |
| September 30, 2016 | -25.55M |
| June 30, 2016 | -22.43M |
| March 31, 2016 | -17.84M |
| December 31, 2015 | -14.78M |
Free Cash Flow Range, Past 5 Years
-119.49M
Minimum
Sep 2023
230.85M
Maximum
Jun 2024
-56.62M
Average
-87.16M
Median
Free Cash Flow Benchmarks
| Johnson & Johnson | 19.02B |
| Assembly Biosciences Inc | 24.10M |
| Precision BioSciences Inc | -48.36M |
| Entrada Therapeutics Inc | -17.46M |
| NovaBay Pharmaceuticals Inc | -4.812M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -27.86M |
| Cash from Investing (Quarterly) | -208.71M |
| Cash from Financing (Quarterly) | 12.05M |
| Free Cash Flow Per Share (Quarterly) | -0.4636 |
| Free Cash Flow to Equity (Quarterly) | -28.64M |
| Free Cash Flow to Firm (Quarterly) | -28.64M |
| Free Cash Flow Yield | 9.04% |